{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=32",
    "query": {
      "intervention": "Placebo once daily",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 5498,
    "total_pages": 550,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T21:03:13.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00773552",
      "title": "Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Urge",
        "Urge Incontinence",
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "solifenacin succinate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stamford Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 45 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2008-11",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2016-12-06",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 2,
      "location_summary": "Stamford, Connecticut",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773552"
    },
    {
      "nct_id": "NCT01412658",
      "title": "Clinical Safety of a Novel Milk Protein Peptide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Safety"
      ],
      "interventions": [
        {
          "name": "Hydrolyzed milk protein mixture",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Glycerol placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Ambryx Biotechnology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "35 Years to 60 Years"
      },
      "enrollment_count": 73,
      "start_date": "2006-11",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2011-08-09",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 1,
      "location_summary": "Waco, Texas",
      "locations": [
        {
          "city": "Waco",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01412658"
    },
    {
      "nct_id": "NCT05812755",
      "title": "SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Endothelial Dysfunction",
        "Vascular Diseases",
        "Kidney Injury",
        "Brain Disease",
        "Vascular Inflammation"
      ],
      "interventions": [
        {
          "name": "Vericiguat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2023-05-19",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05812755"
    },
    {
      "nct_id": "NCT00108485",
      "title": "Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Kidney Failure, Chronic",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Extended release niacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2005-04",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108485"
    },
    {
      "nct_id": "NCT00811889",
      "title": "Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Bardoxolone Methyl (RTA 402)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 227,
      "start_date": "2009-04-30",
      "completion_date": "2010-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Chula Vista, California + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811889"
    },
    {
      "nct_id": "NCT05267535",
      "title": "Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Piromelatine 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurim Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 216,
      "start_date": "2022-06-15",
      "completion_date": "2024-12-12",
      "has_results": true,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 32,
      "location_summary": "Costa Mesa, California • Long Beach, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267535"
    },
    {
      "nct_id": "NCT04286789",
      "title": "Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Low dose ORTD-1",
          "type": "DRUG"
        },
        {
          "name": "Low dose vehicle control",
          "type": "DRUG"
        },
        {
          "name": "High dose ORTD-1",
          "type": "DRUG"
        },
        {
          "name": "High dose vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oryn Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-22",
      "completion_date": "2021-10-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Tustin, California • Miami, Florida",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04286789"
    },
    {
      "nct_id": "NCT03136991",
      "title": "A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "AZD4831",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 38,
      "start_date": "2017-05-15",
      "completion_date": "2017-11-22",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03136991"
    },
    {
      "nct_id": "NCT07840326",
      "title": "A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Progressive Multiple Sclerosis",
        "Primary Progressive MS",
        "Primary Progressive Multiple Sclerosis (PPMS)",
        "Secondary Progressive MS (SPMS)",
        "Secondary Progressive Multiple Sclerosis (SPMS)",
        "Secondary Progressive MS",
        "Non-Active SPMS",
        "Non-Active Secondary Progressive Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity"
      ],
      "interventions": [
        {
          "name": "SUN-627",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sundance Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-10",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07840326"
    },
    {
      "nct_id": "NCT01054443",
      "title": "A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Thrombocytopenia (ITP)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lusutrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-03-18",
      "completion_date": "2010-11-24",
      "has_results": true,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-10-17T21:03:13.470Z",
      "location_count": 19,
      "location_summary": "Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01054443"
    }
  ]
}